Baird analyst Joel Beatty lowered the firm’s price target on BeyondSpring to $1.25 from $4 and keeps an Outperform rating on the shares. The analyst ssaid the reduction comes from removing plinabulin completely from our model, after approval was denied in China in 1Q23 and a CRL from the FDA was issued in 2021.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BYSI: